TNX Tenax International S.p.A.
Tenax International S.p.A. engages in the designing and production of low-voltage electric road sweepers and street washers in Italy and internationally. The company provides manual street sweepers, electric urban vacuum…
Industry Peers
Auto Manufacturers| Headline | Source | Time |
|---|---|---|
Older | ||
 Tenax (TENX) Found a 26.3-Meter Benefit in a Prespecified Subgroup After LEVEL Missed Its Primary Endpoint. Is Another Phase 3 Trial Viable? Tenax Therapeutics, Inc. (NASDAQ:TENX) has a possible route forward for TNX-103, but the Phase 3 LEVEL trial did not establish efficacy in the overall population. The study evaluated oral levosimendan in 241 patients with pulmonary hypertension associated with heart failure with preserved ejection fraction, or PH-HFpEF. At Week 12, the adjusted improvement in six-minute walk […] | ||
 Tenax Therapeutics’ stock crashes on Phase III trial failure Despite the miss, a subgroup of patients with more severe disease showed more meaningful benefit - data Tenax plans to submit to the FDA and EMA. | ||
 Tenax LEVEL Trial Misses Primary Goal, but Subgroup Data Bolsters Levosimendan Case Tenax Therapeutics (NASDAQ:TENX) reported that its Phase III LEVEL trial of oral levosimendan in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction, or PH-HFpEF, did not meet its primary endpoint, though the company said subgroup, biomarker and hemody | ||
 Tenax Therapeutics Phase 3 LEVEL Trial Misses Primary Endpoint for TNX-103 The pivotal study failed to show a statistically significant improvement in exercise capacity or its key secondary symptom endpoint, although prespecified subgroup and biomarker findings are prompting Tenax to pursue a revised registrational strategy with the FDA. Key Investor TakeawaysTenax Therapeutics (NASDAQ:TENX) said its Phase 3 LEVEL trial of TNX-103 did not meet the primary 6-minute walk distance endpoint or the key secondary KCCQ symptom endpoint. | ||
 Tenax, Sionna Shares Sink After Trial Failures Shares of Tenax Therapeutics and Sionna Therapeutics tumbled Monday after the biotechs revealed separate late-stage trial failures. Tenax stock fell nearly 90% after a Phase 3 trial of its experimental heart-failure pill failed to help patients walk farther than those on a placebo. | ||
 Why Did TENX Stock Crash 89% Today? The biotech firm’s experimental drug TNX-103 failed to meet the main goal of a late-stage study in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction. | ||
Tenax, Sionna plunge; MarineMax jumps premarket on reported buyout Investing.com - U.S. stock index futures edged higher on Monday, while Dow futures were little changed, as investors scaled back hopes for a breakthrough in the Middle East and looked ahead to key inflation data due later this week for fresh clues on the Federal Reserve’s interest rate path. | ||